Impedimed Limited (AU:IPD) has released an update.
ImpediMed Limited reported a mixed financial year in 2024, with total revenue dipping by 9% to $10.3 million, attributed to the end of a significant Astra Zeneca trial. However, the company’s core SOZO business saw a revenue rise of 14%, alongside an increase in annual recurring revenue and the number of tests conducted. The firm’s renewed commercial strategy and leadership team have led to a notable 77% increase in U.S. unit sales in Q4, indicating a promising turnaround.
For further insights into AU:IPD stock, check out TipRanks’ Stock Analysis page.
